Compare DuPont de Nemours Inc (DD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs ResMed Inc. — how do they compare? DuPont de Nemours Inc trades at $130.23 (market cap $17.89B), while ResMed Inc. trades at $230.49 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and DuPont de Nemours Inc pays the higher dividend (1.81%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and ResMed Inc. for 51 Days on average.
| DD | RMD | |
|---|---|---|
Market Cap | $17.89B | $31.89B |
Volume | 816,409 | 618,314 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $277.88 |
52-Week Low | $92.49 | $182.82 |
Typical Hold Time | 89 Days | 51 Days |
Enterprise Value | $19.28B | $31.24B |
Dividend Yield | 1.81% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $130.53, down 0.42% on the day, with a neutral technical signal and bearish moving average trend. The company reported a net loss of $779 million in 2025 despite beating EPS estimates in recent quarters, with revenue declining to $6.85 billion. Analyst consensus is bullish with 59% buy ratings, though the consensus price target of $95 is below the current price. Recent news highlights innovation in Tyvek materials and digital tools, alongside legal settlements over PFAS contamination.
The outlook is mixed: strong analyst support and product innovation offer upside, but recent profitability challenges, high P/E ratio, and legal liabilities pose risks. Earnings growth and margin recovery are critical for sustaining investor confidence amid volatile cash flows and competitive pressures.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
